Absci Corp. (ABSI) has drawn attention with compelling preclinical data for its lead program, ABS-201, an AI-designed antibody targeting the prolactin receptor. The recent findings demonstrated that ABS-201 stimulates hair growth by regenerating the stem cell niche and promoting key growth modulators in translational human scalp models.
With the Phase 1/2a HEADLINE trial now underway and interim results anticipated in 2026, Absci is positioning ABS-201 as a potential breakthrough therapy for androgenetic alopecia, a condition affecting millions with limited treatment options.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.